Amphastar Pharmaceuticals (AMPH)
(Delayed Data from NSDQ)
$21.21 USD
+0.26 (1.24%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $21.21 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth C Momentum A VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
AMPH 21.21 +0.26(1.24%)
Will AMPH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AMPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AMPH
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
Bausch Health (BHC) Lags Q2 Earnings Estimates
AMPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Amphastar (AMPH) a New Buy Stock
Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?
Here's Why Amphastar (AMPH) is Poised for a Turnaround After Losing 13.1% in 4 Weeks
Other News for AMPH
Amphastar Pharmaceuticals: Shares Are Interesting, And Options Even More
Amphastar Pharmaceuticals Inc (AMPH) Announces Second Quarter 2025 Earnings Release and ...
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August ...
Amphenol (AMPH) Anticipates Strong Q3 Revenue Growth Amid Electronics Boom | AMPH Stock News
Amphastar sees Q3 adjusted EPS 77c-79c, consensus 69c